Catherine Diefenbach, MD, Director, Clinical Lymphoma Program, Perlmutter Cancer Center @nyulangone discusses the unmet needs of the Phase 1/2 study investigating obinutuzumab in relapsed/refractory follicular lymphoma.
Unmet Needs in the Management of Follicular Lymphoma @nyulangone
